Condition
Keratinocyte Skin Cancer
Total Trials
3
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 4 (1)
Trial Status
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06627036Phase 4RecruitingPrimary
Dermoscopy vs Standard Marking for the Completeness of Excision of Keratinocyte Skin Cancers: The ClearMark Trial
NCT06064019Not ApplicableRecruitingPrimary
Evaluation of Nevisense as Support Tool for the Diagnose of Keratinocyte Skin Cancer
NCT03607578Not ApplicableCompleted
Test of Interventions to Prevent Skin Cancer Among Danes on Vacation in High UV Index Sunny Destinations
Showing all 3 trials